KCL-286 Cuts Alzheimer’s Damage in Mice, Targeting 2 Early Disease Pathways
Updated
Updated · ScienceAlert · Jul 13
KCL-286 Cuts Alzheimer’s Damage in Mice, Targeting 2 Early Disease Pathways
3 articles · Updated · ScienceAlert · Jul 13
Summary
KCL-286 reduced two early Alzheimer’s hallmarks in mice—DNA damage and brain inflammation—in a new FEBS Open Bio study using Tg2576 animals prone to amyloid-beta buildup.
Three treated mice received the drug three times a week from 15 to 18 months, and brain analysis showed stronger double-strand break repair alongside higher BRCA1, a key DNA-repair factor.
The drug also appeared to calm overactive microglia and improve astrocyte changes, suggesting it affects the immune response linked to neurodegeneration rather than only one molecular target.
KCL-286 has already cleared Phase 1 safety and tolerability testing in healthy men, and researchers said its oral, blood-brain-barrier-crossing profile could shorten the path toward Alzheimer’s trials.
This drug targets cancer-like mutations in brain cells. What are the hidden risks of this new approach?
This Alzheimer's therapy fights core aging processes. Could it also prevent normal cognitive decline in healthy individuals?
A new drug targets DNA damage for Alzheimer's. Is the decades-long war on amyloid plaques finally over?
KCL-286 Advances Alzheimer’s Therapy: Novel RARβ Agonist Shows Promise in DNA Repair, Inflammation Reduction, and Human Trials
Overview
KCL-286, developed by King's College London researchers, is a promising new drug candidate for Alzheimer's disease. It is being studied for its unique ability to repair cellular damage, specifically DNA double-strand breaks, which are thought to play an early and critical role in the progression of Alzheimer's. Building on previous research showing its effectiveness in repairing DNA damage in neuropathic pain, scientists believe KCL-286 could target similar pathways in Alzheimer's. This focus on repairing fundamental cellular damage marks a new direction in Alzheimer's research, aiming to address the root causes of the disease rather than just managing symptoms.